U.S. flag

An official website of the United States government

NM_000465.4(BARD1):c.415A>G (p.Lys139Glu) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Mar 15, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000131410.13

Allele description [Variation Report for NM_000465.4(BARD1):c.415A>G (p.Lys139Glu)]

NM_000465.4(BARD1):c.415A>G (p.Lys139Glu)

Gene:
BARD1:BRCA1 associated RING domain 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2q35
Genomic location:
Preferred name:
NM_000465.4(BARD1):c.415A>G (p.Lys139Glu)
HGVS:
  • NC_000002.12:g.214781459T>C
  • NG_012047.3:g.33253A>G
  • NM_000465.4:c.415A>GMANE SELECT
  • NM_001282543.2:c.358A>G
  • NM_001282545.2:c.215+15602A>G
  • NM_001282548.2:c.158+27953A>G
  • NM_001282549.2:c.364+10838A>G
  • NP_000456.2:p.Lys139Glu
  • NP_001269472.1:p.Lys120Glu
  • LRG_297t1:c.415A>G
  • LRG_297:g.33253A>G
  • LRG_297p1:p.Lys139Glu
  • NC_000002.11:g.215646183T>C
  • NG_012047.2:g.33246A>G
  • NM_000465.2:c.415A>G
  • NM_000465.3:c.415A>G
  • NR_104212.2:n.380A>G
  • NR_104215.2:n.323A>G
  • p.K139E
Protein change:
K120E
Links:
dbSNP: rs587782395
NCBI 1000 Genomes Browser:
rs587782395
Molecular consequence:
  • NM_001282545.2:c.215+15602A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001282548.2:c.158+27953A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001282549.2:c.364+10838A>G - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000465.4:c.415A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001282543.2:c.358A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NR_104212.2:n.380A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_104215.2:n.323A>G - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000186386Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)		Uncertain significance
(Nov 19, 2022) 		germlineclinical testing

Citation Link,

SCV000688200Color Diagnostics, LLC DBA Color Health
criteria provided, single submitter

(ACMG Guidelines, 2015)		Uncertain significance
(Mar 15, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From Ambry Genetics, SCV000186386.9

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The p.K139E variant (also known as c.415A>G), located in coding exon 4 of the BARD1 gene, results from an A to G substitution at nucleotide position 415. The lysine at codon 139 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Color Diagnostics, LLC DBA Color Health, SCV000688200.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

This missense variant replaces lysine with glutamic acid at codon 139 of the BARD1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with BARD1-related disorders in the literature. This variant has been identified in 1/249728 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024